Peptide Research Database

Access 7,487 peer-reviewed studies, clinical trials, and research papers on peptides. Filter by key research, study type, compound, and category. Direct links to full PubMed entries for comprehensive, evidence-based exploration.

In Vitro
PMID: 43009799
2026 Nov 10

Elevated circulating activin A is associated with disease severity in advanced steatotic liver disease (SLD).

In lab experiments, activin A was associated with liver stiffness and was higher in participants with SLD-related cirrhosis.

Hedin K, Nasr P, Iredahl F, Forsgren M, Rådholm K, Dahlström N, Stjernman H, Sjögren D, Rejler M, Leinhard OD, Lundberg P, Kechagias S, Jönsson C, Ekstedt M

Steatotic liver disease (SLD) is a major contributor to the global burden of chronic liver disease and is linked to liver fibrosis. Emerging evidence implicates activin A in this process, but its role remains unclear due to conflicting findings. This cross-sectional study examines circulating levels of activin A and its endogenous inhibitor follistatin in individuals with metabolic dysfunction and evaluates their associations with clinical indicators of steatosis and fibrosis. Plasma activin A and follistatin were measured with ELISA in 309 participants with type 2 diabetes (T2D) with or without SLD and in 97 participants with SLD-related cirrhosis. Hepatic fat was assessed using 1H-MRS-PDFF or MRI-PDFF, or if unavailable, controlled attenuation parameter (CAP). Liver stiffness was measured with vibration-controlled transient elastography (VCTE). In the diabetes cohort, participants with steatosis and fibrosis had higher activin A concentrations than participants with neither steatosis nor fibrosis (0.400 ng/mL vs. 0.285 ng/mL, P = 0.036). In the cirrhosis cohort, activin A correlated strongly with liver stiffness (ρ = 0.696, P < 0.001). Participants with VCTE suggestive of compensated advanced chronic liver disease (cACLD) and clinically significant portal hypertension (CSPH) exhibited significantly higher activin A concentrations than participants without (0.546 vs. 0.307 ng/mL, P < 0.001 and 0.624 vs. 0.396 ng/mL, P < 0.001, respectively). In this study, neither follistatin nor the activin A-to-follistatin ratio​ was associated with steatosis or fibrosis. Activin A was associated with liver stiffness and was higher in participants with SLD-related cirrhosis.

BMC gastroenterology
Other
PMID: 43003421
2026 Nov 09

Two-Year Trajectories of DIAL2-Predicted Cardiovascular Risk After Initiation of Semaglutide, Empagliflozin or Their Combination: The DIAL-STEP Study.

This study found repeated DIAL2 and its explanatory decompositions do not establish fewer cardiovascular events or superiority of a treatment strategy.

Labate AM, Villari P

To describe observed clinical changes and trajectories of DIAL2-predicted cardiovascular risk during 24 months of oral semaglutide, empagliflozin or combination treatment. This retrospective cohort included 332 adults without prior cardiovascular disease (semaglutide, 139; empagliflozin, 106; combination, 87). The primary endpoint was the investigator-defined HIGH category (calculated 1-year risk ≥ 3%); continuous risk was secondary. Generalized estimating equations and linear mixed models assessed trajectories. Sensitivity models added baseline age, sex and their time interactions or baseline predicted risk. Age-fixed and Shapley calculations were exploratory. Paired 24-month changes included HbA1c -1.13 percentage points (95% CI: -1.27 to -1.00), systolic blood pressure -7.64 mmHg (-9.48 to -5.79), total cholesterol -20.28 mg/dL (-23.84 to -16.73) and weight -3.91 kg (-4.40 to -3.41). Standard DIAL2 was valid for 329, 327 and 325 participants across visits. HIGH prevalence was 24.6%, 23.2% and 23.7%, without a time-by-treatment interaction (p = 0.731). The continuous-risk interaction was significant (p = 0.002; demographic-time-adjusted p = 0.006). In 324 complete cases, standard predicted risk changed from 2.172% to 2.052% (relative change -5.5%); holding age fixed yielded 1.777% at 24 months (-18.2%). These relative changes concern calculated probabilities. Glycaemia and several other measured risk factors improved during follow-up. Categorical DIAL2 status remained broadly stable, while continuous estimates varied with risk-factor changes and chronological age. Repeated DIAL2 and its explanatory decompositions do not establish fewer cardiovascular events or superiority of a treatment strategy.

Diabetes, obesity &amp; metabolism
Animal Study
Notable
PMID: 43001579
2026 Nov 09

Early nutrition impacts later setmelanotide treatment of obesity in mice.

In a mouse study, unhealthy nutrition in early life can reduce response to a weight loss drug in adult obesity.

Baidoe-Ansah D, Mayer A, Mattern J, Ritter K, Klinghammer N, Cantacorps L, Chesters RA, Falck JE, Yagoub S, Zhu J, Felsberg J, Lippert RN

Unhealthy nutrition in early life can reduce response to a weight loss drug in adult obesity.

Clinical Trial
Highly Cited
PMID: 43003902
2026 Nov 09

Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial.

In a randomized trial, in conclusion, resistance exercise training reduced loss of total lean soft tissue mass, representing an effective adjunct to tirzepatide anti-obesity therapy.

Green DJ, Haynes A, Underwood DR, Winterton ER, Green AA, Daly RM, George ES, Lester L, Naylor LH, Hillis GS, Fegan PG, Yeap BB

Incretin mimetics as obesity therapy induce substantial weight and fat loss but also decrease lean soft tissue mass, possibly impairing skeletal muscle function. Here, in this two-arm randomized controlled trial of adding resistance exercise (REx) to tirzepatide (T), 120 adults with overweight or obesity were treated with tirzepatide and randomized to thrice-weekly resistance exercise training or usual activities for 40 weeks. Tirzepatide was safe, and most participants tolerated up-titration to 15 mg weekly. Adherence to resistance exercise was 91%. Weight loss achieved was similar (T = -22.61 kg, T+REx = -22.28 kg, P = 0.694). For primary outcomes, loss of total fat mass was similar (T = -17.19 kg, T+REx = -17.98 kg, P = 0.700; between-group difference = -0.77 kg, 95% confidence interval (CI): -2.14 kg to 0.60 kg), but resistance exercise reduced loss of total lean soft tissue mass (T = -4.67 kg, T+REx = -3.57 kg, P < 0.001; between-group difference = 1.09 kg, 95% CI: 0.43-1.75 kg). For related endpoints, resistance exercise reduced loss of appendicular lean soft tissue mass (T = -3.55 kg, T+REx = -2.92 kg, P < 0.001). Upper and lower body muscle strength decreased with tirzepatide (bench press -4.09 kg, lat pulldown -4.42 kg, knee extension -4.42 kg) but increased with T+REx (+4.68 kg, +8.58 kg, +5.88 kg, respectively, all P < 0.001 versus tirzepatide). In conclusion, resistance exercise training attenuated loss of total lean soft tissue mass, representing an effective adjunct to tirzepatide anti-obesity therapy. Australian New Zealand Clinical Trials Registry identifier: ACTRN12623001236684 .

Nature medicine
Other
PMID: 43003406
2026 Nov 09

Effectiveness of GLP-1 RAs and SGLT-2is for Weight Loss and Glycaemic Control: An Observational Emulation of a Target Trial.

This study found our analyses benchmark the results of short-term randomized trials and extend the evidence to longer periods.

Silverbeck J, Roitman E, Vodonos Zilberg A, Balicer R, Dagan N, Hernán MA

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT-2is) are both recommended as second-line treatments for individuals with Type 2 diabetes and obesity, but long-term head-to-head randomized trials in this population are lacking, necessitating a real-world evaluation of their relative benefits in weight loss and glycaemic control. Using observational data from Clalit's medical records, separate target trials were emulated comparing three GLP-1 RAs (liraglutide, dulaglutide and semaglutide) with SGLT-2is in individuals with Type 2 diabetes and obesity. The main outcomes were absolute changes in body weight and HbA1c during follow-up (up to 5 years for liraglutide/dulaglutide and 3 years for semaglutide). We used inverse-probability weighting to adjust for potential confounders. We identified 4296, 11 159 and 5041 eligible individuals initiating liraglutide, dulaglutide and semaglutide, respectively. Long-term weight loss was similar (6.4-7.3 kg at 5 years) for liraglutide and dulaglutide compared with SGLT-2is; weight loss for semaglutide was 2.6 kg (95% CI: 1.2-4.0) greater than for SGLT-2is at 18 months. At 18 months, HbA1c reductions were 0.4% (95% CI: 0.3-0.5), 0.7% (95% CI: 0.6-0.8) and 0.6% (95% CI: 0.5-0.8) greater for liraglutide, dulaglutide and semaglutide than SGLT-2is, respectively; this advantage was maintained throughout follow-up. We estimated that, compared with SGLT-2is, liraglutide and dulaglutide provided superior glycaemic control and similar weight reduction over 5 years, and that semaglutide produced greater short-term reductions in both outcomes. Our analyses benchmark the results of short-term randomized trials and extend the evidence to longer periods.

Diabetes, obesity &amp; metabolism
Clinical Trial
Highly Cited
PMID: 43000069
2026 Nov 09

Disentangling semaglutide's effects on motivation in major depressive disorder: A mediation analysis.

In a clinical study, limitations include the post-hoc design, small effective sample, unadjusted comparisons, and functional unblinding. Examined whether this effect is statistically mediated by metabolic change.

Gill H, Badulescu S, Shah H, Brudner RM, Di Vincenzo JD, Tabassum A, Phan L, Teopiz KM, López CL, Rosenblat JD, McIntyre RS, Mansur RB

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve effort-based decision-making in major depressive disorder (MDD), but whether this reflects their metabolic effects is unknown. We examined whether this effect is statistically mediated by metabolic change. Exploratory, post-hoc secondary analysis of a 16-week, double-blind, placebo-controlled trial (NCT04466345) of adjunctive oral semaglutide versus placebo in 72 adults with MDD and overweight/obesity. The Effort-Expenditure for Rewards Task yielded an effort-discounting parameter (k) via a subjective-value model. Mediation by change in body mass index, percent body fat, glycated hemoglobin, and insulin resistance (HOMA-IR) was tested using bootstrapped mediation models (n = 46-53) and generalized estimating equations (GEE; n = 33-36), with depressive-symptom and cognition change as competing mediators. No adjustment was made for multiple comparisons. Semaglutide significantly reduced effort discounting (GEE treatment × visit β = -1.78; 95% CI, -3.34 to -0.23; P = .025). Modeling metabolic change did not attenuate this effect; the total indirect effect was opposite in sign to the direct effect (+2.04; direct, -2.93), a suppression pattern that did not survive exclusion of high-influence observations. Depressive-symptom and cognitive change did not account for the effect; reverse models showed no mediation of metabolic improvement by Δk. Semaglutide's effect on effort-based decision-making in MDD was not statistically mediated by the metabolic variables assessed, nor by change in depressive symptoms or cognition. These exploratory findings are consistent with a weight-independent effect but do not establish a central mechanism. Limitations include the post-hoc design, small effective sample, unadjusted comparisons, and functional unblinding.

Journal of affective disorders
Other
PMID: 43003413
2026 Nov 09

Persistent Gaps in Semaglutide and Tirzepatide Prescribing Among Adults With Class III Obesity Without Type 2 Diabetes.

Kang B, Choi K, Yang H, Kim C, Krumholz HM, Lu Y

Diabetes, obesity &amp; metabolism
Other
PMID: 43002037
2026 Nov 09

Ensemble-Based Segmental Helical Organization in an Aib-Rich Lipidated Peptide: Biomacromolecular Insights from High-Field NMR.

This study found these findings provide a residue-specific view of tirzepatide dynamics in solution and offer structural insights into the conformational landscape of this therapeutically important peptide. Performed a solution NMR investigation of tirzepatide to establish residue-specific resonance assignments and characterize its conformational properties in an aqueous solution.

Nordin N, Choi J, Lee J, Kim EH, Ryu EK, Ryu KS, Lee D, Hwang E, Bang JK, Cheong HK

Tirzepatide (TZP) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has demonstrated remarkable therapeutic efficacy for the treatment of type 2 diabetes and obesity. Despite its clinical importance, residue-specific information on its solution conformation remains limited due to its structural complexity, including noncanonical amino acids and a lipidated side chain. In this study, we performed a solution NMR investigation of tirzepatide to establish residue-specific resonance assignments and characterize its conformational properties in an aqueous solution. Backbone and side-chain resonances were assigned using multidimensional NMR spectroscopy, including 1H-15N HMQC, TOCSY, and NOESY experiments. Reliable sequential NOE connectivities were identified for several peptide segments, while ambiguous and unresolved resonances were conservatively excluded from the structural interpretation. The N-terminal Aib2 residue served as an important assignment anchor but did not define a stable terminal structure. In contrast, the Aib13 region exhibited a locally organized backbone environment with a short helical-like conformational tendency, suggesting Aib13-centered local ordering within the peptide chain. Structure calculations based on the 1.2 GHz NMR and CD experiments revealed that tirzepatide does not adopt a single rigid conformation in solution but instead exists as a conformational ensemble composed of locally ordered and flexible regions. These findings provide a residue-specific view of tirzepatide dynamics in solution and offer structural insights into the conformational landscape of this therapeutically important peptide.

Biomacromolecules
Review
Notable
PMID: 43003168
2026 Nov 09

Linking skin to system: LL-37 as a potential molecular link between psoriasis and its comorbidities.

In a research review, therefore, investigating strategies targeting LL-37 holds promising application prospects for the treatment of psoriasis and its related conditions.

Deng G, Luo Y, Wu W, Ru Y, Song J, Zhang Z, Ma X, Kuai L, Li B, Zhang Y, Ding X

Antimicrobial peptides (AMPs) are a crucial component of the host immune defense system. Recent evidence has revealed that the antimicrobial peptide LL-37 exhibits a broad range of biological functions, including immunomodulatory roles in various diseases such as infectious diseases, cancers, cardiovascular diseases, and dermatological disorders. This review comprehensively examines the mechanisms of LL-37 in psoriasis and its comorbidities, highlighting its position within the disease network. Firstly, we elucidate the dual identity of LL-37 in psoriasis as both an antimicrobial peptide and an autoantigen, as well as its mechanism in mediating the inflammatory process of psoriasis through interactions with neutrophil extracellular traps (NETs) and self-nucleic acids. Furthermore, we analyze the reasons behind its paradoxical pro-inflammatory and anti-inflammatory properties. Importantly, we discuss the potential involvement of LL-37 in psoriasis-associated comorbidities and the underlying mechanisms suggested by current evidence. Therefore, investigating strategies targeting LL-37 holds promising application prospects for the treatment of psoriasis and its comorbidities.

Autoimmunity reviews
Case Report
Notable
PMID: 43030876
2026 Nov 09

Longitudinal Serum and Cerebrospinal Fluid S100B Concentrations After Aneurysmal Subarachnoid Hemorrhage: An Exploratory Comparison of Historical Cohorts With and Without Cerebrolysin Exposure.

In a case report, conclusions: CBL exposure was associated with persistently lower serum S100B concentrations, whereas no corresponding overall between-cohort difference was observed in CSF. Investigated longitudinal serum and cerebrospinal fluid (CSF) S100 calcium-binding protein B (S100B) profiles according to CBL exposure.

Burzyńska M, Lebiedzińska A, Kędziora J, Dragan B, Lechowicz-Głogowska B, Adamik B, Wełna M, Goździk W

Background/Objectives: Cerebrolysin (CBL) has been proposed to exert neuroprotective and neurotrophic effects, but its biological effects after aneurysmal subarachnoid hemorrhage (aSAH) remain uncertain. We investigated longitudinal serum and cerebrospinal fluid (CSF) S100 calcium-binding protein B (S100B) profiles according to CBL exposure. Methods: This retrospective, single-center exploratory cohort study included 67 patients with aSAH (CBL, n = 26; non-CBL, n = 41). S100B was measured in serum and, when CSF access was clinically available, in CSF on days 1, 3, 5, 7, and 10. In the CBL cohort, treatment was initiated before the first study sample, which was obtained approximately 12 h after the first dose on average. Accordingly, day 1 was considered an early post-exposure measurement rather than a pre-treatment baseline. Longitudinal serum and CSF S100B concentrations were analyzed using linear mixed-effects models with patient-specific random intercepts, including CBL exposure, study day, and their interaction. A sensitivity analysis was performed after exclusion of day 1. Results: A significant overall between-cohort difference in serum S100B was observed across the study period (geometric mean ratio [GMR] 0.028, 95% CI 0.013-0.057; p < 0.001), with no significant CBL-by-day interaction (p = 0.218). The association persisted after exclusion of day 1 (GMR 0.023, 95% CI 0.011-0.049; p < 0.001). No significant overall between-cohort difference was observed for CSF S100B (GMR 0.542, 95% CI 0.185-1.584; p = 0.263). The CSF-to-serum ratio was higher in the CBL cohort on days 1, 3, 5, and 7 but not on day 10. No significant between-group differences were observed in delayed cerebral ischemia (DCI), TCD-detected cerebral vasospasm, mortality, or functional outcomes. Conclusions: CBL exposure was associated with persistently lower serum S100B concentrations, whereas no corresponding overall between-cohort difference was observed in CSF. These findings indicate a differential association of CBL exposure with serum and CSF S100B profiles; however, because CBL exposure was completely confounded by treatment era, the observed associations cannot establish a causal treatment effect. Prospective, contemporaneous controlled studies are required to determine whether CBL directly influences S100B dynamics after aSAH.

Journal of clinical medicine